By Mariam Sunny (Reuters) -The U.S. Food and Drug Administration has approved Elanco Animal Health’s oral drug to protect dogs against six parasitic infections, the company said on Monday. The drug, branded as Credelio Quattro, is a single, monthly chewable tablet for dogs eight weeks of age or older, the company said. The drug is […]
Health
US FDA approves Elanco’s treatment for parasitic infections in dogs
Audio By Carbonatix
By Mariam Sunny
(Reuters) -The U.S. Food and Drug Administration has approved Elanco Animal Health’s oral drug to protect dogs against six parasitic infections, the company said on Monday.
The drug, branded as Credelio Quattro, is a single, monthly chewable tablet for dogs eight weeks of age or older, the company said.
The drug is approved for the treatment of flea and tick infestations, along with roundworm, hookworm and tapeworm infections. It is also approved to prevent flea infestations and heartworm disease in dogs.
The company expects to launch the drug in the first quarter of 2025.
“We see this innovation will expand the market … and we will price it according to that value proposition,” CEO Jeff Simmons told Reuters in an interview.
Elanco expects Credelio Quattro to become one of its potential blockbusters, along with the recently launched Zenrelia, its first product in the market related to skin disease treatments for dogs.
The currently available paraciticide treatments for dogs include Boehringer Ingelheim’s Nexgard Plus and Zoetis’ Simparica Trio, which offer protection against fleas, ticks, heartworm disease, roundworms and hookworms.
(Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)